CA2752702A1 - Dosage permettant de determiner les profils epigenetiques des marqueurs d'alleles de l'x fragile - Google Patents

Dosage permettant de determiner les profils epigenetiques des marqueurs d'alleles de l'x fragile Download PDF

Info

Publication number: CA2752702A1
Authority: CA; Canada
Prior art keywords: seq; methylation; nucleotide sequence; epigenetic; fragile
Prior art date: 2009-02-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2752702A

Other languages

English (en)

Inventor

David Eugeny Godler

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Murdoch Childrens Research Institute

Original Assignee

Murdoch Childrens Research Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-17

Filing date

2010-02-17

Publication date

2010-08-26

2009-02-17 Priority claimed from AU2009900668A external-priority patent/AU2009900668A0/en

2010-02-17 Application filed by Murdoch Childrens Research Institute filed Critical Murdoch Childrens Research Institute

2010-08-26 Publication of CA2752702A1 publication Critical patent/CA2752702A1/fr

Status Abandoned legal-status Critical Current

Links

230000001973 epigenetic effect Effects 0.000 title claims abstract description 117
238000003556 assay Methods 0.000 title claims abstract description 62
108700028369 Alleles Proteins 0.000 title description 44
238000000034 method Methods 0.000 claims abstract description 109
230000002068 genetic effect Effects 0.000 claims abstract description 97
230000004049 epigenetic modification Effects 0.000 claims abstract description 88
230000001575 pathological effect Effects 0.000 claims abstract description 72
238000012216 screening Methods 0.000 claims abstract description 23
239000003795 chemical substances by application Substances 0.000 claims abstract description 20
208000036626 Mental retardation Diseases 0.000 claims abstract description 18
238000004590 computer program Methods 0.000 claims abstract description 9
238000007069 methylation reaction Methods 0.000 claims description 325
230000011987 methylation Effects 0.000 claims description 324
125000003729 nucleotide group Chemical group 0.000 claims description 167
239000002773 nucleotide Substances 0.000 claims description 166
101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 124
102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims description 122
210000004027 cell Anatomy 0.000 claims description 110
208000001914 Fragile X syndrome Diseases 0.000 claims description 102
230000000295 complement effect Effects 0.000 claims description 71
230000008859 change Effects 0.000 claims description 61
108090000623 proteins and genes Proteins 0.000 claims description 51
230000007170 pathology Effects 0.000 claims description 43
238000006243 chemical reaction Methods 0.000 claims description 38
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
238000011144 upstream manufacturing Methods 0.000 claims description 34
201000010099 disease Diseases 0.000 claims description 33
238000013518 transcription Methods 0.000 claims description 28
230000035897 transcription Effects 0.000 claims description 28
238000012545 processing Methods 0.000 claims description 26
230000008995 epigenetic change Effects 0.000 claims description 17
230000035772 mutation Effects 0.000 claims description 16
210000001766 X chromosome Anatomy 0.000 claims description 15
208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims description 14
238000004891 communication Methods 0.000 claims description 13
238000000491 multivariate analysis Methods 0.000 claims description 13
230000000626 neurodegenerative effect Effects 0.000 claims description 13
230000001123 neurodevelopmental effect Effects 0.000 claims description 13
230000003542 behavioural effect Effects 0.000 claims description 12
238000007473 univariate analysis Methods 0.000 claims description 12
208000017924 Klinefelter Syndrome Diseases 0.000 claims description 11
206010003805 Autism Diseases 0.000 claims description 9
208000020706 Autistic disease Diseases 0.000 claims description 9
210000001776 amniocyte Anatomy 0.000 claims description 9
238000007419 epigenetic assay Methods 0.000 claims description 8
210000005260 human cell Anatomy 0.000 claims description 8
210000004962 mammalian cell Anatomy 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
238000004393 prognosis Methods 0.000 claims description 8
230000004044 response Effects 0.000 claims description 8
102000004190 Enzymes Human genes 0.000 claims description 7
108090000790 Enzymes Proteins 0.000 claims description 7
230000003930 cognitive ability Effects 0.000 claims description 7
238000013500 data storage Methods 0.000 claims description 7
208000027087 primary ovarian insufficiency 1 Diseases 0.000 claims description 7
206010044565 Tremor Diseases 0.000 claims description 6
208000026928 Turner syndrome Diseases 0.000 claims description 6
210000000601 blood cell Anatomy 0.000 claims description 6
210000004252 chorionic villi Anatomy 0.000 claims description 6
206010008025 Cerebellar ataxia Diseases 0.000 claims description 5
208000029726 Neurodevelopmental disease Diseases 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
238000009007 Diagnostic Kit Methods 0.000 claims description 3
239000011232 storage material Substances 0.000 claims description 2
239000003814 drug Substances 0.000 abstract description 4
230000000926 neurological effect Effects 0.000 abstract description 4
108020004414 DNA Proteins 0.000 description 114
108091093088 Amplicon Proteins 0.000 description 95
239000000523 sample Substances 0.000 description 62
239000002609 medium Substances 0.000 description 59
238000004458 analytical method Methods 0.000 description 48
238000002105 Southern blotting Methods 0.000 description 43
238000003752 polymerase chain reaction Methods 0.000 description 34
239000012634 fragment Substances 0.000 description 32
150000007523 nucleic acids Chemical class 0.000 description 32
102000039446 nucleic acids Human genes 0.000 description 30
108020004707 nucleic acids Proteins 0.000 description 30
108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 29
102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 28
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 26
108091029523 CpG island Proteins 0.000 description 24
210000004369 blood Anatomy 0.000 description 24
239000008280 blood Substances 0.000 description 21
239000000969 carrier Substances 0.000 description 21
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 19
108700039691 Genetic Promoter Regions Proteins 0.000 description 17
108020004999 messenger RNA Proteins 0.000 description 17
230000001105 regulatory effect Effects 0.000 description 17
230000003321 amplification Effects 0.000 description 16
238000003199 nucleic acid amplification method Methods 0.000 description 16
230000006870 function Effects 0.000 description 14
230000014509 gene expression Effects 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
108091023040 Transcription factor Proteins 0.000 description 11
102000040945 Transcription factor Human genes 0.000 description 11
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
238000001514 detection method Methods 0.000 description 10
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
108091029430 CpG site Proteins 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
101150082209 Fmr1 gene Proteins 0.000 description 9
241000701044 Human gammaherpesvirus 4 Species 0.000 description 9
238000004422 calculation algorithm Methods 0.000 description 9
230000002596 correlated effect Effects 0.000 description 9
238000012544 monitoring process Methods 0.000 description 9
230000002441 reversible effect Effects 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 8
238000012408 PCR amplification Methods 0.000 description 8
108700009124 Transcription Initiation Site Proteins 0.000 description 8
239000000872 buffer Substances 0.000 description 8
239000011248 coating agent Substances 0.000 description 8
238000000576 coating method Methods 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
108700019146 Transgenes Proteins 0.000 description 7
230000004913 activation Effects 0.000 description 7
206010036601 premature menopause Diseases 0.000 description 7
208000017942 premature ovarian failure 1 Diseases 0.000 description 7
230000000692 anti-sense effect Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
238000005259 measurement Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000010839 reverse transcription Methods 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000003860 storage Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
108010077544 Chromatin Proteins 0.000 description 5
206010061818 Disease progression Diseases 0.000 description 5
206010068052 Mosaicism Diseases 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
210000003483 chromatin Anatomy 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
101150008740 cpg-1 gene Proteins 0.000 description 5
229940104302 cytosine Drugs 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
230000005750 disease progression Effects 0.000 description 5
210000003527 eukaryotic cell Anatomy 0.000 description 5
102000040430 polynucleotide Human genes 0.000 description 5
108091033319 polynucleotide Proteins 0.000 description 5
239000002157 polynucleotide Substances 0.000 description 5
238000003753 real-time PCR Methods 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
238000012549 training Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical class CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 4
102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 description 4
101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 description 4
208000012902 Nervous system disease Diseases 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
238000000137 annealing Methods 0.000 description 4
230000002950 deficient Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000015654 memory Effects 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
238000011002 quantification Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
238000007400 DNA extraction Methods 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108700024394 Exon Proteins 0.000 description 3
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
108010033040 Histones Proteins 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
102100040105 Upstream stimulatory factor 1 Human genes 0.000 description 3
230000021736 acetylation Effects 0.000 description 3
238000006640 acetylation reaction Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
101150071119 cpg-2 gene Proteins 0.000 description 3
230000009849 deactivation Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
230000017858 demethylation Effects 0.000 description 3
238000010520 demethylation reaction Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000007834 ligase chain reaction Methods 0.000 description 3
230000005381 magnetic domain Effects 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
238000002493 microarray Methods 0.000 description 3
230000002981 neuropathic effect Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012420 spiking experiment Methods 0.000 description 3
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
230000010741 sumoylation Effects 0.000 description 3
229940113082 thymine Drugs 0.000 description 3
238000013519 translation Methods 0.000 description 3
TYIRBZOAKBEYEJ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetate Chemical compound C1=CC(C)=CC=C1C(=O)C(N1C)=CC=C1CC(=O)OCCN1C(C(=O)N(C)C(=O)N2C)=C2N=C1 TYIRBZOAKBEYEJ-UHFFFAOYSA-N 0.000 description 2
FDDZTBYOCCYZRR-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-3-phenyl-3h-isoindol-1-one;phosphoric acid Chemical compound OP(O)(O)=O.C12=CC=CC=C2C(=O)N(CCN(CC)CC)C1C1=CC=CC=C1 FDDZTBYOCCYZRR-UHFFFAOYSA-N 0.000 description 2
XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 2
230000007067 DNA methylation Effects 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
102100031702 Endoplasmic reticulum membrane sensor NFE2L1 Human genes 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000588298 Homo sapiens Endoplasmic reticulum membrane sensor NFE2L1 Proteins 0.000 description 2
101000577547 Homo sapiens Nuclear respiratory factor 1 Proteins 0.000 description 2
101000671637 Homo sapiens Upstream stimulatory factor 1 Proteins 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
101100013186 Mus musculus Fmr1 gene Proteins 0.000 description 2
108020004711 Nucleic Acid Probes Proteins 0.000 description 2
238000002123 RNA extraction Methods 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108091023045 Untranslated Region Proteins 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
238000005251 capillar electrophoresis Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
101150014604 cpg-3 gene Proteins 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000012350 deep sequencing Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
235000011180 diphosphates Nutrition 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000020796 long term synaptic depression Effects 0.000 description 2
230000027928 long-term synaptic potentiation Effects 0.000 description 2
238000010801 machine learning Methods 0.000 description 2
238000013507 mapping Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000011880 melting curve analysis Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
108091070501 miRNA Proteins 0.000 description 2
239000002679 microRNA Substances 0.000 description 2
238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 2
230000007472 neurodevelopment Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000002853 nucleic acid probe Substances 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
238000012175 pyrosequencing Methods 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
238000001262 western blot Methods 0.000 description 2
230000003936 working memory Effects 0.000 description 2
101150033839 4 gene Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
101710177131 Activity-regulated cytoskeleton-associated protein Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000143060 Americamysis bahia Species 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101100328096 Caenorhabditis elegans clec-88 gene Proteins 0.000 description 1
102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
102100036646 Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101001072655 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Proteins 0.000 description 1
101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000031942 Late Onset disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
241000736256 Monodelphis Species 0.000 description 1
241000736257 Monodelphis domestica Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
208000036623 Severe mental retardation Diseases 0.000 description 1
102100022978 Sex-determining region Y protein Human genes 0.000 description 1
206010042008 Stereotypy Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
235000010724 Wisteria floribunda Nutrition 0.000 description 1
108700029631 X-Linked Genes Proteins 0.000 description 1
208000028247 X-linked inheritance Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
208000029560 autism spectrum disease Diseases 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
108010025267 calcium-dependent protein kinase Proteins 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
101150093710 clec-87 gene Proteins 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
101150075908 cpg-4 gene Proteins 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000001335 demethylating effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
210000003520 dendritic spine Anatomy 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
230000036732 histological change Effects 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000006607 hypermethylation Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
210000001739 intranuclear inclusion body Anatomy 0.000 description 1
201000003723 learning disability Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
125000001805 pentosyl group Chemical group 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical group 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
108010026466 polyproline Proteins 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000001303 quality assessment method Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000025915 regulation of apoptotic process Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000011273 social behavior Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
230000003977 synaptic function Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/125—Bisulfite(s)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Pathology (AREA)
Immunology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA2752702A 2009-02-17 2010-02-17 Dosage permettant de determiner les profils epigenetiques des marqueurs d'alleles de l'x fragile Abandoned CA2752702A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
AU2009900668A AU2009900668A0 (en)		2009-02-17	An assay
AU2009900668		2009-02-17
AU2009901041A AU2009901041A0 (en)		2009-03-11	An assay II
AU2009901041		2009-03-11
PCT/AU2010/000169 WO2010094061A1 (fr)	2009-02-17	2010-02-17	Dosage permettant de déterminer les profils épigénétiques des marqueurs d'allèles de l'x fragile

Publications (1)

Publication Number	Publication Date
CA2752702A1 true CA2752702A1 (fr)	2010-08-26

Family

ID=42633345

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2752702A Abandoned CA2752702A1 (fr)	2009-02-17	2010-02-17	Dosage permettant de determiner les profils epigenetiques des marqueurs d'alleles de l'x fragile

Country Status (6)

Country	Link
US (1)	US20120094288A1 (fr)
EP (1)	EP2398917B1 (fr)
AU (1)	AU2010215061B2 (fr)
CA (1)	CA2752702A1 (fr)
IL (1)	IL214690A (fr)
WO (1)	WO2010094061A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130210007A1 (en) *	2010-08-11	2013-08-15	Murdoch Childrens Research Institute	Treatment and diagnosis of epigenetic disorders and conditions
EP2723902A4 (fr) *	2011-06-24	2015-02-18	Murdoch Childrens Res Inst	Traitement et diagnostic de troubles et d'états pathologiques épigénétiques
US20130017544A1 (en) *	2011-07-11	2013-01-17	Advanced Liquid Logic Inc	High Resolution Melting Analysis on a Droplet Actuator
EP2948565B1 (fr) *	2013-01-25	2018-10-10	Murdoch Childrens Research Institute	Dosage pour quantifier le degré de méthylation d'un site cible
CN103981254B (zh) *	2014-03-27	2016-05-18	江苏佰龄全基因生物医学技术有限公司	一种脆性x综合症临床快速pcr检测试剂盒
CN104059981A (zh) *	2014-07-03	2014-09-24	上海中优医药高科技有限公司	一种frm1基因cgg序列重复的检测方法及应用
EP3299456A1 (fr) *	2016-09-26	2018-03-28	Université de Strasbourg	Gène dgkk recombinant pour thérapie génique du syndrome x-fragile
GB201810897D0 (en) *	2018-07-03	2018-08-15	Chronomics Ltd	Phenotype prediction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
CA1323293C (fr)	1987-12-11	1993-10-19	Keith C. Backman	Essai utilisant la reorganisation d'une sonde a l'acide nucleique dependant d'une matrice
ATE138106T1 (de)	1988-07-20	1996-06-15	David Segev	Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
GB2225112A (en)	1988-11-22	1990-05-23	Ici Plc	Hybridisation probes
US5427930A (en)	1990-01-26	1995-06-27	Abbott Laboratories	Amplification of target nucleic acids using gap filling ligase chain reaction
CA2035010C (fr)	1990-01-26	1996-12-10	Keith C. Backman	Methode d'amplification des acides nucleiques cibles applicable aux reactions en chaine a la polymerase et a la ligase
US5455166A (en)	1991-01-31	1995-10-03	Becton, Dickinson And Company	Strand displacement amplification
AU8997991A (en)	1991-01-31	1992-08-06	Becton Dickinson & Company	Exonuclease mediated strand displacement amplification
US6180337B1 (en) *	1991-05-24	2001-01-30	Baylor College Of Medicine	Diagnosis of the fragile X syndrome
DE19712332A1 (de) *	1997-03-25	1998-10-01	Boehringer Mannheim Gmbh	Verfahren zum Nachweis von Mikrosatelliten-Instabilität zur Tumordiagnostik
US6143504A (en)	1998-10-27	2000-11-07	Arch Development Corporation	Methods and compositions for the diagnosis of fragile X syndrome
US20060024676A1 (en) *	2003-04-14	2006-02-02	Karen Uhlmann	Method of detecting epigenetic biomarkers by quantitative methyISNP analysis
US7906288B2 (en) *	2006-01-04	2011-03-15	The Johns Hopkins University	Compare-MS: method rapid, sensitive and accurate detection of DNA methylation
US8163480B2 (en) *	2006-10-05	2012-04-24	Quest Diagnostics Investments Incorporated	Nucleic acid size detection method
WO2009045467A1 (fr) *	2007-10-02	2009-04-09	Fred Hutchinson Cancer Research Center	Procédés et compositions pour l'identification de risque accru de développement de troubles liés à l'x fragile

2010
- 2010-02-17 US US13/202,085 patent/US20120094288A1/en not_active Abandoned
- 2010-02-17 EP EP10743317.9A patent/EP2398917B1/fr active Active
- 2010-02-17 CA CA2752702A patent/CA2752702A1/fr not_active Abandoned
- 2010-02-17 AU AU2010215061A patent/AU2010215061B2/en active Active
- 2010-02-17 WO PCT/AU2010/000169 patent/WO2010094061A1/fr not_active Ceased
2011
- 2011-08-16 IL IL214690A patent/IL214690A/en active IP Right Grant

Also Published As

Publication number	Publication date
EP2398917A4 (fr)	2012-07-25
AU2010215061A1 (en)	2011-09-08
IL214690A0 (en)	2011-11-30
AU2010215061A2 (en)	2013-11-14
AU2010215061B2 (en)	2016-07-14
EP2398917A1 (fr)	2011-12-28
US20120094288A1 (en)	2012-04-19
EP2398917B1 (fr)	2016-10-05
WO2010094061A1 (fr)	2010-08-26
IL214690A (en)	2017-05-29

Legal Events

Date	Code	Title	Description
2015-03-05	EEER	Examination request	Effective date: 20150212
2017-04-02	FZDE	Discontinued	Effective date: 20170217

Publication	Publication Date	Title
US20140212873A1 (en)	2014-07-31	Treatment and diagnosis of epigenetic disorders and conditions
US10138521B2 (en)	2018-11-27	Treatment and diagnosis of epigenetic disorders and conditions
JP5219516B2 (ja)	2013-06-26	染色体異数性の検出方法
AU2010215061B2 (en)	2016-07-14	Assay for determining epigenetic profiles of markers of Fragile X alleles
US20120100995A1 (en)	2012-04-26	Biomarkers for Autism Spectrum Disorders
US20100075308A1 (en)	2010-03-25	Polymorphisms in genes affecting cns disorders and uses thereof
KR20100020960A (ko)	2010-02-23	자궁내막증과 연관된 유전자 마커 및 이의 용도
US20130338032A1 (en)	2013-12-19	Assay for determining epigenetic profiles of markers of fragile x alleles
US20070141577A1 (en)	2007-06-21	Method
AU2014210369B2 (en)	2020-02-06	An assay for quantitating the extent of methylation of a target site
KR20140123468A (ko)	2014-10-22	복부비만 예측용 ｓｎｐ 마커 및 이의 용도
KR102543907B1 (ko)	2023-06-15	치주질환 위험도 평가용 유전자 마커
US20090208928A1 (en)	2009-08-20	Method and device for the in vitro detection of polycystic ovarian syndrome (pcos) and pathologies involving cardiovascular risk
US20220017963A1 (en)	2022-01-20	Methods, Compositions and Systems for Detecting PNPLA3 Allelic Variants
KR20150092937A (ko)	2015-08-17	한국인의 고혈압 예측용 ｓｎｐ 마커
WO2005024064A2 (fr)	2005-03-17	Procede pour detecter l'autisme et des troubles analogues
JP5263919B2 (ja)	2013-08-14	メタボリック症候群の検査方法
US20080194419A1 (en)	2008-08-14	Genetic Association of Polymorphisms in the Atf6-Alpha Gene with Insulin Resistance Phenotypes
KR20150115700A (ko)	2015-10-14	한국인의 고혈압 예측용 ｓｎｐ 마커
US20050176006A1 (en)	2005-08-11	Genetic markers for bone mass
KR20250118434A (ko)	2025-08-06	알츠하이머병 발병 위험도 예측을 위한 레이 복잡도 지연 회상 점수 저하와 관련이 있는 단일염기다형성 마커 및 이의 용도
US7488582B2 (en)	2009-02-10	Nucleic acids and associated diagnostics